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Essentials
• Fibrinolysis inhibitors are localized in advanced atheroma by immunohistology of endarterectomies.
• Neovascular endothelium/neocapillaries show thrombinactivatable fibrinolysis inhibitor (TAFI).
• Macrophage areas show free plasminogen activator inhibitor (PAI-1), notably in the vulnerable part.
• Free PAI-1 and TAFI stabilize active plaque area by inhibition of fibrinolysis and inflammation.
Summary. Background: Fibrinolysis plays an important role in destabilization of atherosclerotic plaques and is tightly regulated by specific inhibitors. Objective: The fibrinolysis inhibitors plasminogen activator inhibitor type-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) were quantified and described in the morphological context of advanced carotid plaques American Heart Association VI-VIII to elucidate their role in plaque stability. Methods: Immunohistochemistry in serial sections along the longitudinal axis of endarterectomies from patients with symptomatic carotid stenosis (n = 19) were studied using an antibody specific for free PAI-1 (I205), an antibody with high affinity for TAFI/TAFIa (CP17) and established antibodies for smooth muscle cells (a-actin), endothelial cells (von Willebrand factor [VWF]), macrophages (CD68) and platelets (CD42). Results: PAI-1 and TAFI show a specific distribution in these advanced plaques with a maximum corresponding to the internal carotid artery (ICA). Free PAI-1 was mainly detected in macrophages and in intravascular thrombi, and TAFI in endothelial cells (ECs) but also macrophages. The one-way ANOVA analysis with Bonferroni's correction showed a significant increase of macrophages and ECs, TAFI and PAI-1 in areas with high neovascularization in endarterectomy sections corresponding to ICA. High Spearman factors for TAFI, PAI-1 and VWF indicate neovascularization as the main source of plasma proteins, transported by platelets into the atheroma (PAI-1) or expressed by ECs (TAFI). CD68 was highly associated with VWF, PAI-1 and especially TAFI, underlining the role of macrophages in fibrinolytic activity and inflammation. Conclusion: The abundance of free PAI-1 and TAFI in the plaque may inhibit plasmin generation and thereby counteract plaque destabilization by fibrinolysis, cell migration and inflammation.
Introduction
Development of atheroma from intimal thickening to a life threatening occlusion is a long lasting and intricate process of the vasculature, influenced by blood rheology and hemostasis [1, 2] . The plaque structure changes with time, undergoing remodeling while growing and maturing into complex morphology [3] . Atherosclerotic changes of the vessel wall are characterized by inflammation, degradation of extracellular matrix components and neovascularization [4] . The degree of carotid artery stenosis, as analyzed by ultrasound, is linearly related to the risk of ischemic stroke and risk reduction by endarterectomy is still the main therapeutic intervention for stroke prevention [5, 6] . Stroke is always related to thrombosis, and fibrinolytic therapy to dissolve blood clots by tissue-type plasminogen activator (t-PA) is the first-line approach in acute stroke [7, 8] . Plasmin, the key enzyme of the fibrinolytic system, is involved in tissue remodeling and degradation in atheroma [9] . Upon demand t-PA is locally secreted from the endothelium and converts plasminogen into the active enzyme plasmin, which degrades fibrin [10, 11] . Inhibition of the fibrinolytic system may occur directly at the level of plasmin by a 2 -antiplasmin, or indirectly by the plasminogen activator inhibitor type-1 (PAI-1), binding irreversibly to t-PA [12, 13] . Moreover, the thrombin-activatable fibrinolysis inhibitor (TAFI), activated to TAFIa by thrombin or plasmin, digests free lysine residues on the fibrin surface, thereby preventing binding and thus activation of plasminogen to plasmin [14] [15] [16] . High plasma levels of TAFI, produced by the liver as pre-proenzyme (pre-TAFI), are seen as risk factors for cardiovascular disease (CVD) in dyslipidemia, metabolic syndrome and diabetes patients [17, 18] . In prospective cohort studies, elevated PAI-1 plasma levels have been associated with the risk of coronary heart disease [19] and PAI-1 has been suggested as an independent risk factor for CVD in type 2 diabetes [20] . PAI-1 antigen has previously been localized to human plaque, adjacent to the necrotic core [21, 22] . TAFI in human atherosclerotic plaque has been described, together with the endothelial cell (EC) marker CD31 (PECAM-1) [23] . The aim of this study was to localize and quantify both these fibrinolysis inhibitors, free PAI-1 and TAFI, in the cellular context of advanced carotid atherosclerotic plaque, at different loci along the longitudinal axis. Furthermore, we aimed to explore the association of these inhibitors with morphological data, such as calcification, neovascularization, intraplaque hemorrhage (IPH), total plaque area and the American Heart Association (AHA) classification, in order to contribute histological data on the role of fibrinolysis in plaque vulnerability.
Methods

Study samples
The Gothenburg Atheroma Study Group (GASG) is a biobank consisting of clinical information, blood, plasma, serum and endarterectomies from patients with symptomatic carotid stenosis. In-toto extirpated carotid artery plaques from 19 patients (demographic data are given in Table S1 ) were subjected to immunohistochemical (IHC) and morphological analysis. All patients had moderate to severe carotid stenosis (>70% occlusion), as determined by carotid duplex ultrasonography, and increased plasma lipoprotein levels, inflammation-and fibrinolysis markers (Table S2 ).
All subjects received both written and oral information before providing consent to participate in the study. The protocol was approved by the Regional Ethics Review Board at Sahlgrenska University Hospital, Gothenburg, Sweden. The study was performed according to the Guidelines of the World Medical Association Declaration of Helsinki.
Tissue handling
Endarterectomies, between 20 and 45 mm long, were fixed in formalin immediately after surgical removal and cut into~3 mm blocks, starting at the carotid artery bifurcation (bulb) ( Figure S1 ). Each block was embedded in paraffin and serial transverse 4-lm sections were taken for morphological analysis and IHC [3] . Thus, multiple consecutive sections from the different blocks of the plaque from each patient were subjected to sequential staining for six markers and hematoxylin/eosin (HTX-E).
Primary antibodies
In Table S3 all primary antibodies that is mouse monoclonal, rabbit polyclonal and sheep polyclonal antibodies (mAb; pAb) are listed. CD68 is a common marker for both macrophages and foam cells but does not allow differentiation of the macrophage subtypes that are described in atherosclerotic plaque [24] . The a-actin mAb is a marker both for smooth muscle cells (SMC) and precursors such as pericytes [25] . Endothelial cells have been targeted by VWF, except for double staining, where CD31 and CD34, respectively have been used. The specific, commercially available PAI-1 mAb I205 is unique because it recognizes free PAI-1, both latent and active, but not the irreversible complex with either t-PA or u-PA [26] (Table S4 ). The TAFI antibody (CP17) was developed by immunization of rabbits with the immunogenic peptide of TAFI, amino acid 71-85, spanning the activation site for TAFIa (aa76/77). Immune sera were screened by ELISA on recombinant TAFI [27] , as previously described [28] . The antibody, purified by affinity chromatography on (aa71-85)-Sepharose and characterized by Western blot on recombinant TAFI, provided a strong staining pattern for TAFIa ( Figure S2 ). CP17 was further characterized by Biacore on different related carboxypeptidases in addition to TAFI, TAFIa and denatured TAFIa (Figurez S3), confirming TAFIa as the main antigen. The immunohistochemically characterization [29] of CP17 is presented in the Supplement (Figures S4-S6 ) and the TAFI/EC double-staining in Fig. 7 .
Histopathological classification and immunohistochemical analysis
One section from each 3-mm block, stained with HTX-E to enhance the general morphology, was analyzed to cover the longitudinal distribution of neovascularization, calcification, IPH, the AHA classification [30] . All primary antibodies were selected and titrated in a pilot study, with special emphasis on the PAI-1 antibodies. Controls without primary antibodies, respectively a rabbit IgG fraction were run for each protocol, resulting in consistently negative observations. The stained endarterectomy cross-sections were scanned to digitalized images using a Zeiss Mirax Scanner (Zeiss, Jena, Germany). These digital images of the whole crosssection were analyzed using the BioPix software (BioPix AB, Gothenburg, Sweden). Figure S6 provides further information about the image analysis. Semi-quantitative assessment of the immunoreactive signal was performed and expressed as percentage stained area of the total plaque area (Table S5) .
Statistical analysis
For the statistical analysis, the results from two adjacent 3-mm blocks were used to calculate the mean value of the percentage stained area for a-actin, CD68, VWF, CD42, TAFI and PAI-1 and the total section area or categorical value for AHA class, IPH, neovascularization and calcification. The mean of the two adjacent 3-mm blocks corresponding to the internal carotid artery (ICA) above the bulb was called ICA1, the next two blocks were merged to ICA2 and the two most distant blocks (at 12-18 mm) merged to ICA3. The same numbering was used for the common carotid artery (CCA) ( Figure S1 ). Because there is less plaque along the CCA side, only CCA1 and CCA2 data are available. Furthermore, pooled data for the three main parts of the plaque, CCA, bulb and ICA, were compared.
Results are presented as mean AE SEM. One-way ANOVA followed by Bonferroni's correction for multiple comparisons was used in the statistical analyses; P < 0.05 was regarded as statistically significant. Additionally, Spearman correlation analysis was conducted for all analyzed sections and parameters.
Results
Pilot-study for selection of antibodies
In a pilot study, antibodies used in this study (Table S3) were selected and titrated on tissue sections from a CCA block. In Fig. 1 , sections are presented that show the differences between total PAI-1 and free PAI-1 in comparison to t-PA-and TAFI/TAFIa. The overview shows staining for t-PA with the mAb C5 (Fig. 1A) , for total PAI-1 with the mAb CLB-2C8 (Fig. 1D) , for free PAI-1 with the mAb I205 ( Fig. 1G ) and for TAFI/TAFIa with the pAb CP17 (Fig. 1J ). Intensive staining is seen for t-PA and total PAI-1, with a similar distribution. The TAFI/TAFIa stained area is apparently different from t-PA and total PAI-1 and of medium intensity. At 209 magnification (Fig. 1B ,E,H,K) cholesterol crystals are visible (not stained). Both TAFI/TAFIa and free PAI-1 show a distinct cellular distribution close to this area. In a more differentiated picture (Fig. 1C ,F,I,L), free PAI-1 and TAFI/TAFIa are seen in macrophages. In contrast, neither t-PA nor total PAI-1 stained macrophages but are distributed in the surrounding fibrotic tissue.
Plaque morphology and longitudinal distribution of cellular markers and fibrinolysis inhibitors
All plaques contained advanced lesions, type VI to VIII according to the AHA classification [30] . Morphological findings in this material correlated with findings from ultrasonography, that numerous plaques were large and advanced with an almost occluded lumen. Neovascularization was observed frequently and IPH was found in all plaques. These findings are consistent with the clinical data ( Table S1 ): 80% of patients have had TIA or stroke and a proatherogenic lipoprotein profile (Table S2) . High plasma concentrations of VWF or PAI-1 were not associated with the percentage stained area for these markers.
Staining was performed on cross-sections along the longitudinal axis of the plaques and neovascularization, calcification and IPH were categorically estimated. For the statistical analysis and the graphical presentation of the results, we used the mean values for two adjacent 3-mm blocks for all parameters evaluated and by this reduced the number of measuring points to six. One-way ANOVA analysis was conducted to compare the data for these six points, followed by Bonferroni's correction for multiplicity (Table S6 and Figure S8 ). For further statistical evaluation we reduced the points to three by pooling all results for CCA and ICA to compare them with each other and with the bulb (Table 1) .
The longitudinal distribution for all parameters is shown in Fig. 2 . The AHA classification, generally ranging from VI to VIII ( Fig. 2A) , scored significantly higher at the bulb (P = 0.023) and even at ICA (P = 0.037) compared with CCA (for all P-values in this section see Table 1 ). The total plaque area was significantly larger at the bulb (P = 0.022) compared with ICA as well as with CCA (P = 0.03). The cellular markers a-actin, CD68, CD42 and VWF are differently distributed (Fig. 2C,D) . Macrophages (CD68) and platelets (CD42) were significantly elevated in ICA compared with CCA (P = 0.026 and P = 0.032, respectively). SMC stained by a-actin are uniformly present throughout the whole plaque. VWF, PAI-1 and TAFI are very similar in their distribution pattern (Fig. 2D ) and similar to the CD68 profile (Fig. 2C ). There was a slight increase (ns) of all three markers from CCA to the bulb, followed by a maximum at ICA, highly significant for VWF and PAI-1 (P = 0.009 and 0.003) and with a P-value of 0.035 for TAFI. For the morphological data investigated (Fig. 2B) , ICA is significantly different from CCA for neovascularization (P = 0.011), with a tendency for an increase already at the bulb (P = 0.055) compared with CCA. Calcification is significantly increased at the bulb (P = 0.001) compared with CCA; for IPH no significant differences were found. Immunohistological micrographs from the pilot study for tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI). Staining of an endarterectomy sample at the common carotid artery (CCA) level with the antibody (A-C) C5 for t-PA, (D-F) CLB-2C8 for total PAI-1, (G-I) I205 for free PAI-1 and (J-L) CP17 for TAFI/ TAFIa. At 209 magnification (box marked in A) an area with non-stained cholesterol crystals close to a neovessel is seen (B,E,H,K) and at 409 magnification (box marked in B) the staining of free PAI-1 (I) in macrophages/foam cells, whereas t-PA (C) and total PAI-1 (F) are mainly located in the surrounding tissue rather than in the macrophages/foam cells.
Spearman correlation of fibrinolysis inhibitors and cellular and morphological markers
Spearman correlation analysis was conducted with the data of all analyzed sections for the fibrinolysis inhibitors, cellular markers and morphological features, including AHA classification (Fig. 3) . The immunostained areas of TAFI/TAFIa and PAI-1 are significantly associated, which is confirmed by the Spearman coefficient (R = 0.78; P < 0.001). Both areas correlate significantly with VWF (R = 0.74 for PAI-1; R = 0.73 for TAFI) and even CD42 is significantly associated with VWF (R = 0.74), underlining the close proximity of these entities, the fibrinolysis inhibitors, platelets and EC. The most pronounced marker, however, is CD68, which highly correlates with TAFI/TAFIa, PAI-1 and VWF. Neovascularization and IPH show a Spearman factor of 0.77, whereas none of the markers is associated with SMC.
Localization of fibrinolysis inhibitors, cellular markers and morphology
Series of consecutive sections were investigated for the location of the different markers. Selected examples for such series from one patient are shown in Figs 4, 5 and 6. Serial sections stained for the six markers and HTX-E show the general distribution of the fibrinolysis inhibitors in relation to the cellular constituents and the morphology. This section (Fig. 4A , overview) located within ICA1, < 6 mm above the bulb, shows an advanced plaque in HTX-E stain with a necrotic core and calcification, a large area of IPH and luminal thrombus formation. An area was selected (large square in Fig. 4A ) in the HTX-E stain (Fig. 4B ) that shows part of a necrotic core, neovascularization, calcified areas, some inflammatory cells and a mural thrombus in the lumen. The four cellular markers characterize the plaque and its different compartments. The SMC area towards the lumen (capsule) and several bands of SMC migrating into the plaque area are stained by a-actin (Fig. 4G ). CD42 is highly expressed in the lumen and in several small vessels (Fig. 4C) . The faint stain of CD42 in the CD68 area within foam cells points to phagocytosed platelets (Fig. 4D) .
CD68 (Fig. 4D ) stains macrophages/foam cells in the area adjacent to the SMC barrier and shows intensive staining in the necrotic core. The VWF antibody (Fig. 4E) stains the luminal endothelium and capillaries in the area of neovascularization.
The two fibrinolysis inhibitors, free PAI-1 and TAFI/ TAFIa, are apparently confined to specific cellular compartments. CP17, the TAFI/TAFIa antibody, stains the luminal endothelium, small vessels, neocapillaries and EC layers (Fig. 4F) , similar to the VWF stain, showing the degree of neovascularization. CP17 also stains acellular areas, representing fibrin precipitation in the amorphous parts of the plaque and belts of collagen/reticular fibers, where TAFI/TAFIa is bound. Free PAI-1 is mainly found in macrophages and foam cells (Fig. 4H ) and in the CD42-positive area, with intensive stain also in intraluminal thrombi.
Another area, from the same section as in Fig. 4 (small square in Fig. 4A) , is shown at 409 magnification in Fig. 5 . A small intraplaque blood vessel shows strong positivity for platelets (CD42) and VWF (Fig. 5A,C) . CP17 provides a distinct EC stain, almost identical to the VWF stain, and faintly stains the lumen and surrounding tissue, as expected for a plasma protein leaking from unstable vasculature. CP17 also stained some discrete structures, probably remnants of EC linings from neovessel turnover (Fig. 5D) . The vessel wall is marked by the a-actin stain as a thin, single SMC layer (Fig. 5E ), showing that this particular vessel is already stabilized by a layer of SMC or pericytes. Only a few macrophages can be seen (Fig. 5B) , some of them strongly stained for free PAI-1 (Fig. 5F ).
To complete this picture, another area from this series of sections (box in Fig. 4B ) is presented at 409 magnification in Fig. 6 . Here an area of active inflammation, characterized by infiltrating lymphocytes and large foam cell/macrophage areas, is seen (Fig. 6B) . The macrophages/foam cells are intensely stained for free PAI-1 (Fig. 6F ), but only weakly for TAFI/TAFIa (Fig. 6D ) and for VWF (Fig. 6C) . VWF and TAFI/TAFIa (Fig. 6D) stain the endothelium and a-actin stains the SMC layer around the vessel. The intraluminal material is stained for CD42 (Fig. 6A), VWF (Fig. 6C ) and TAFI/ TAFIa (Fig. 6D ) and even for PAI-1 (Fig. 6F) . Another set of pictures is found in Figure S7 showing all six markers in relation to neovessel/capillaries in the plaque. Furthermore, double-staining for TAFI/TAFIa and endothelial cells (CD31 and CD34, respectively) in the adventitia of a human aorta further confirms the presence of TAFI/TAFIa in endothelial cells (Fig. 7) .
Discussion
This is the first immunohistological study that describes the distribution of free PAI-1 and TAFI/TAFIa in advanced carotid plaque. We describe an estimate of the relative amounts of these inhibitors in endarterectomies from 19 patients, based on the immunohistologically stained area, relative to the total plaque area (Tabel S5), which is similar to published results, at least for CD68 and a-actin [31, 32] . All carotid plaques were found to contain PAI-1, TAFI/TAFIa, VWF and platelets in addition to the common macrophage and SMC pattern. The longitudinal sectioning and sequential staining of the specimens indicated an increase in fibrinolysis inhibitors in the vulnerable part (CD68 rich and a-actin poor) of the plaque. The amount and longitudinal distribution of TAFI/TAFIa and PAI-1 were similar and both show a maximum in ICA2, 6-12 mm above the bifurcation (Fig. 2D) . The cellular distribution of these two fibrinolysis inhibitors, however, was obviously different. It has not been shown previously by immunohistochemistry that advanced plaques contain free PAI-1 in Fig. 3 . Spearman correlation analysis for all parameters from the endarterectomies (see Fig. 2 ). The morphological parameters, the American Heart Association (AHA) classifications and the different staining data for all sections of the whole plaque have been combined for this analysis. Spearman coefficients are given in the appropriate field and the statistical significance (P-value) by the color of the field. Fig. 5 an area from the plaque (small box in Fig. 4A ) was selected to show the different staining patterns at higher magnification and in Fig. 6 an area of active inflammation is shown (box in Fig. 4B ).
macrophages/foam cells and also in CD42-positive areas in IPH and intraluminal thrombi. Other immunohistochemical studies have shown the presence of PAI-1 in plaque [22, 33] but with PAI-1 antibodies that only detect total PAI-1. Furthermore, increased levels of PAI-1 mRNA in atherosclerotic vessels have been reported [21, [34] [35] [36] . IHC and in situ hybridization of healthy and atherosclerotic human arteries showed PAI-1 mRNA in ECs and SMCs of the arterial media [35] . PAI-1 has probably been transported into the plaque by platelets, which in part have been phagocytosed. Only a faint stain is seen for CD42 in macrophages/foam cells, which are known to be attracted by IPH [37] . Platelets have a short half-life and the CD42 antigen may have escaped detection within macrophages [38] . Probably, most free PAI-1 in the plaque is active, because the large amount of PAI-1 present in platelets mainly consists of active PAI-1 [39] . Stoop et al. [40] have described PAI-1/ vitronectin complexes in atherosclerotic tissue, which supports our assumption that at least part of the free PAI-1 in plaque is active, because only active PAI-1 can bind to vitronectin.
TAFI/TAFIa is seen as a discrete stain in EC, both in stable vessels and neovascularized areas, but also around vessels/capillaries, probably bound to thrombomodulin (TM) on the endothelial surface (Fig. 7) . Recently TAFI has been shown to bind directly to TM, localized on the luminal side of endothelial cells [41] . The question is whether there is TAFI activity in the plaque. The main part of TAFI in plasma, as well as in EC, is not activated [42, 43] . Both plasmin and thrombin, which can convert TAFI into TAFIa, are present in the plaque and TAFI can be activated to TAFIa both by plasmin on the fibrin matrix and by the thrombin-TM complex on the EC surface. The half-life of TAFIa, however, is short, around 10 min in vitro [44] , but might be extended by binding to fibrin, TM and other matrix proteins [18] . Because CP17 preferably binds to TAFIa, we suggest that TAFI activation occurs in the plaque.
Both TAFIa and active PAI-1 can inhibit plasmin generation in the plaque and by this reduce tissue turnover and stabilize the area. Staining of the PAI-1/t-PA complex in advanced plaques suggests that efficient inhibition of fibrinolysis through an excess of PAI-1 might have contributed to plaque stabilization. Although most free PAI-1 in the advanced plaque probably is enclosed in macrophages/foam cells, there is still a fair amount of free PAI-1 in CD42-positive areas and in intraluminal thrombi, close to the t-PA releasing sites. Dependent on the status of neovessels in the plaque, tube formation, stabilization or destruction, more or less t-PA will be released. Alterations in endothelial homeostasis promote atherosclerosis, in part due to increased t-PA/u-PA secretion [11, 45] . Moreover, concomitant reduction of endothelial TAFI might be overcome by infiltrating TAFI from plasma. Which role the fibrinolysis inhibitors play may thus depend on the state of the plaque. This is obvious when comparing Figs 5 and 6. Figure 5 shows a part of the plaque with few inflammatory cells and large areas with free PAI and platelets. In Fig. 6 an inflammatory part of the plaque is shown with almost no platelets, but where all foam cells contain PAI-1 and some also contain TAFI. In such an active plaque, macrophages may prevent the action of the fibrinolysis inhibitors by increased phagocytosis of platelets and EC debris. This supports the theory that these inhibitors may have different roles in different parts of the same plaque, as has been discussed by Oliver et al. [46] .
Neovascularization as a key component in plaque development and vulnerability may lead to increased IPH and platelet and macrophage invasion and support inflammation [47] . Plaques showing more pronounced vascularization and IPH, predict future cardiovascular events [3, 48] . The endothelium is responsible for angiogenesis. ECs migrate from the vasa vasorum into the adventitia, followed by tube formation and microvessel stabilization by pericytes. Therefore, an inhibiting effect of TAFI on in vitro capillary-like tube formation, as described by Guimarãraes [23] , may translate into reduction in neovascularization in vivo. In this scenario, TAFIa could have a stabilizing effect in plaque as a more general modulator of the plasminogen system, because there are lysine-binding sites (LBS) on almost all cell types, that allow binding of plasminogen activators, plasminogen and plasmin [49] . Binding to these plasminogen receptors with C-terminal lysine residues or conformational mimetics (e.g. arginine on cells but also on molecules in the extracellular compartments) may lead to local plasmin production. By cleaving these LBS, TAFIa will influence cell migration, macrophage invasion and inflammation in the plaque [50] . This is in line with other findings that TAFIa acts as an anti-inflammatory compound by cleavage of arginine from complement factors, supporting a link between hemostasis and complement activation [51] .
The rather small number of patients analyzed (n = 19) may somewhat limit the general conclusion from this study; however, the immunohistological analysis can be considered of high quality and analysis of a large number of investigated sections contributes to a consistent read out. Associations with clinical data (Table S1 ) or the increased plasma concentrations of PAI-1 and VWF (Table S2 ) and the IHC data could not be proven.
One of the challenges for these kind of studies is to identify relevant control tissue for symptomatic plaque tissue.
The use of asymptomatic plaques as control tissue in comparative studies is complicated by the fact that such plaques quite often display plaque rupture [52] and are then complicated lesions, albeit asymptomatic. Furthermore, when comparing symptomatic and asymptomatic plaques from different individuals, the large inter-individual variations in plaque structure must be considered. Normal arterial segments are not the right choice because endarterectomies are just the plaque without the carotid vessel wall.
Categorical semi-quantitative microscopic scoring was used for the morphological parameters calcification, IPH, neovascularization and the AHA classification. Although categorical scoring may be considered a limitation, these data complete the overall picture very well. Assessment of markers in histological sections, quantitative or semiquantitative, is anyway very difficult to compare with other publications because of differences in antibodies used, section thickness, staining techniques and the evaluation method. Because we intended to analyze associations between the different markers and compare the different parts of the plaques, this was the method of choice. Even for cellular markers, this method was preferred because, for example, a-actin, CD42, CD68 and VWF positivity in plaques does not necessarily indicate intact SMC, platelets, macrophages or EC, but may detect these markers (or their remnants) where they end up in plaque matrix, clots, IPH and fatty streaks. In summary, there was a rational for including assessment of staining in both extracellular and intracellular compartments in the evaluation.
Conclusion
It is a remarkable finding that the fibrinolysis inhibitors TAFI and free PAI-1 are present in considerable amounts in carotid plaques, with the highest levels corresponding to the vulnerable part of the plaque, adjacent to an area with high macrophage/foam cell content and substantial neovascularization. Free PAI-1 is probably transported into the plaque by platelets and is found in foam cells together with engulfed platelets. The high concentration of free PAI-1 could ensure the inhibition of t-PA/u-PA released from stressed EC. Also, the presence of TAFI could be seen as a safeguard against plasmin generation and thereby prevent fragmentation of the fibrin network, keeping the plaque intact. TAFI is mainly expressed in ECs but is widely distributed, generally in fibrotic areas, probably resulting from leaky neovessels. TAFI is also found in foam cells, probably derived from phagocytosed ECs from disintegrated vessels. Even if both inhibitors enter the plaque as a result of neovascularization, as a hallmark of plaque instability, both inhibitors may play a role in plaque stabilization by controlling plasmin generation, thereby preventing fibrinolysis but also cell migration and inflammation, and potentially counteract the destabilizing effect of neovessel formation. Kalies, K. Wahlander, and J. Deinum are former employees of AstraZeneca.
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